Delivery Order SPE2DR25D3012-SPE2DR26F4F3C
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $9,773.14 to supply 50 mg TNKASE kits to be delivered to the company's corporate office location in Conshohocken, Pennsylvania. The award, issued on October 31, 2025, is structured as a firm fixed price delivery order with an ultimate completion date of November 3, 2025. This non-competitive award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a $15,336.51 firm fixed-price delivery order to AmerisourceBergen Drug Corp for TNKASE 50 MG kits on January 12, 2026, with an ultimate completion date of January 13, 2026. This non-set-aside contract represents a task order under AmerisourceBergen's parent company Cencora, Inc.'s substantial Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999,999,999.00 through December 2031. The pharmaceutical distributor, headquartered in...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $30,093.90, is a Firm Fixed Price Delivery Order for the supply of 4560863049 TNKASE 50 MG KITS. The contract has an ultimate completion date of May 9, 2023. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a Delivery Order valued at $9,163.82 under an Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) Troop Support Medical. The contract is for the provision of 4,563,486,792 TNKASE 50 MG KITS, a pharmaceutical product, with a performance period ending on January 31, 2024. The contract is a Firm Fixed Price arrangement and was awarded on January 30, 2024 without any set-aside...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $17,135.96 by the Defense Logistics Agency (DLA) on September 11, 2025, for the supply of Tankase 50 mg kits. The contract is a firm fixed-price delivery order with an ultimate completion date of September 12, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This award was not designated as a set-aside contract and was competitively awarded through open procurement. This...
- The Defense Logistics Agency awarded a delivery order valued at $9,773.14 to AmerisourceBergen Drug Corp for TNKASE 50 mg kits, with performance in Conshohocken, Pennsylvania and an ultimate completion date of November 5, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and was executed on November 4, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical...
- Amerisourcebergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $92,138.57 on January 7, 2026, with an ultimate completion date of January 8, 2026. The contract, issued under a firm fixed-price arrangement with no set-aside designation, is funded by the Defense Logistics Agency's Medical Supply Chain, a defense-focused federal agency responsible for supplying pharmaceutical products and medical commodities to...
- Amerisourcebergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $35,732.46 on January 19, 2026, by the Defense Logistics Agency's Medical Supply Chain. This firm fixed-price, non-set-aside contract has an ultimate completion date of January 20, 2026, and represents a task order under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical. The parent company, Cencora, Inc. (doing business...
- Amerisourcebergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, has been awarded a delivery order valued at $135,934.08 by the Defense Logistics Agency's Medical Supply Chain. This firm fixed-price contract, awarded on January 15, 2026, with an ultimate completion date of January 16, 2026, represents a competitive award with no set-aside designation. The award falls under Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- Amerisourcebergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $1,011.99 by the Defense Logistics Agency's Medical Supply Chain on January 12, 2026, with an ultimate completion date of January 13, 2026. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a task order under Amerisourcebergen's larger Indefinite Delivery Contract with DLA Troop Support...
- SPE2DR25D3012Indefinite Delivery Contract
- SPE2DR25D3012-SPE2DR26F4F3CDelivery Order
Amerisourcebergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a delivery order from the Defense Logistics Agency valued at $30,997.65 for Tnkase 25 mg vials. The contract, awarded on January 20, 2026, with an ultimate completion date of January 21, 2026, utilizes firm fixed-price pricing and was competitively awarded without set-aside designation. This delivery order is executed under Amerisourcebergen Drug Corp's substantial Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. The award reflects Amerisourcebergen Drug Corp's critical role in the federal medical supply chain, particularly for Defense Health Agency and military treatment facilities. The parent organization, Cencora, Inc. (operating as Amerisourcebergen), holds the overarching $999,999,999.00 IDC with DLA through December 31, 2031, enabling the delivery of an extensive range of pharmaceutical products, specialty medications, brand-name and generic drugs, vaccines, and medical supplies to support military healthcare operations globally. This transaction exemplifies the company's consistent capability to fulfill government pharmaceutical procurement requirements through competitive, open bidding processes.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $31.0k | 1/19/26 |